

Foldable Hydrophilic Intraocular Lens (Sterile)

# i-CTDIFF IOL +3.5

### DESCRIPTION

The i-CTDIFF IOL +3.5 is a Clear Foldable Hydrophilic Intraocular Lens. This hydrophilic one piece posterior chamber IOLs is manufactured from a medical grade acrylate co-polymer with a 360-degree square edge. The trifocal IOL provides three focal points. The surface of the lens has been modified, combination of two profiles offers the patient an intermediate vision without impairing near and distance visual acuities This concept was designed in order to reduce the loss of light energy. The edges of the lenses are made square edged to reduce the occurrence of Posterior Capsular Opacification.

Optic Material Clear Hydrophilic Acrylate Co-polymer Optic Design


: Modified refractive diffractive and Aspheric surface

Haptic Configuration Diopter range

: Modified plate or modified C haptic : +0 to +40 in 0.5 increments (Standard range +5 to +30) : +3.5 D (near vision) and +1.8 D (Intermediate vision)

Addition Refractive Distance focus Diffractive Near focus Diffractive Intermediate focus :20%

Refractive Index Estimated A-Constant 1 465 : 118.2



Multifocal Intraocular Lens (IOL) is intended for primary implantation for the visual correction of aphakia secondary to removal of a cataractous lens with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. The lens is intended to be placed in the capsular bag

-1.5

-0.5

1.5

2 Defocus (D)

0.5

### PATIENT POPULATION

Cataract patients 18 years of age or above

-2.5

## MODE OF ACTION

The Foldable hydrophilic IOL is intended to be positioned in the posterior chamber of the eye, replacing the natural crystalline lens. This position allows the lens to function as a refractive medium in the correction of aphakia. These biconvex optic IOLs have an aspheric apodized diffractive structure on the anterior surface. The biconvex aspheric optic reduces spherical aberration as compared to a standard spherical optic in an average eye

# CLINICAL BENEFIT

The summary of safety and clinical performance will be added in IFU, Once the SSCP is reviewed by notified body and uploaded in EUDAMED.

### CONTRAINDICATIONS

Implantation is not advisable when the IOL may aggravate an existing condition, interfere with the diagnosis or the treatment of pathology or present a risk to the sight of the patient. Among those conditions are but not limited to the following:

- Chronic or recurrent uveitis
- Proliferative diabetic retinopathy
- Corneal endothelial dystrophy Acute eye disease or infection, external or internal Severe complication during surgery
- Choroidal hemorrhage
- Non-age-related cataract Microphthalmos

- Suspected microbial infection Medically uncontrolled glaucoma
- Severe optic atrophy Uncontrollable positive pressure
- Amblyopia

Patients with preoperative ocular conditions such as (but not limited to the following) chronic drug miosis, glaucoma, amblyopia, diabetic retinopathy, previous corneal transplant, previous retinal detachment may not achieve the visual acuity of patients without such problems. The surgeon must determine the potential risk/benefit to be derived from IOL implantation when such conditions exist. such conditions exist.

### POTENTIAL COMPLICATIONS AND SIDE EFFECTS

As with all surgical procedures, cataract surgery with IOL implantation can presents risks. The surgeon must evaluate risk/benefit ratio. Some of the potential complications of cataract surgery are but not limited to the following:

- Wound leak
- Retinal detachment
- Cystoid macular edema Corneal decompensation
- Corneal edema
- Pupillary block
- Iritis
- Corneal endothelial damage
- Endophthalmitis
- Iris prolapse
- Hypopyon
- Glaucoma Capsular rupture
- Vitreous loss
- Lens decentration Subluxation
- Secondary surgical interventions include, but are not limited to: TASS, halos, night glares lens repositioning, lens replacement, vitreous aspirations or iridectomy for pupillary block, wound leak repair, & retinal detachment repair. Some of the listed complications may require second surgical intervention

Note 1- The device does not contain ED/CMR substances

2-The implanted IOL does not contain any metallic components and are safe with no potential for interaction with the Magnetic Resonance (MR) Field.

- IOL should be only implanted by experienced surgeon. The IOL is intended to be used by qualified ophthalmic surgeon only
  The IOL style, dioptric power and expiration date should be verified before opening the
- blister/case for use

- Do not use the device if the sterile package has been opened or damaged
  Do not re-sterilize the lens. Product integrity may compromise
  Do not reuse the IOL. If reused, it may lead to toxic effects, it may lose its performance characteristics, or it may produce infection
- The safety and performance of posterior chamber lens, has not been established for its use in anterior chamber. Implantation of posterior chamber lens in the anterior chamber may produce unsafe results
- Unused medical device waste and consumables should be sent to local waste management regulatory body for disposal

### **DIRECTION FOR USE**

- Prior to opening the box, verify the label for correct model, dioptric power and the expiration date
- After opening the box, verify case label information (model, dioptric power and serial number) and make sure it is consistent with the information printed on the outer box.
- This device is sterile until the inner pouch is opened. Inspect the pouch carefully for any
- In case tears, cuts, punctures, or other similar sign is observed, chances are that the pouch is opened or damaged. DO NOT implant the IOL if the sterility has been compromised. To remove the lens, open the pouch and transfer the case to a sterile environment. Carefully open the case to expose the lens in aseptic environment. To minimize the occurrences of marks on the lens surface during handling, the instruments
- being used for handling the lens should be gently used. Any forceps used for handling the lens must have round edges and a smooth surface. While removing lens from the case, DO NOT grasp the optical area with forceps. The IOL should only be handled from the haptics. Handle the lens carefully to avoid damage to the lens surface or breaking of haptics. DO NOT attempt to reshape the device in any way.
- Rinse the lens thoroughly using sterile intraocular irrigating solution.

  DO NOT rinse the IOL in solutions other than sterile intraocular irrigating solution. Prior to insertion, the IOL should be carefully examined to ensure no particles have adhered on
- instrument surfaces e.g. forceps
  The IOL should be stored at room temperature as recommended in the product IFU.
  I MEDICAL OPHTHALMIC INTERNATIONAL HEIDELBERG GMBH recommends using the lens delivery system manufactured by I MEDICAL OPHTHALMIC INTERNATIONAL HEIDELBERG GMBH.
- Kindly follow instructions given in Injector-Cartridge Information leaflet (IFU) for use of IOL
- delivery system
  To facilitate IOL insertion viscoelastic solution should be used

The IOL is supplied in heat sealed blister containing 0.9 % normal saline solution. A package sterilized with steam sterilization and must be opened only under aseptic conditions.

### CALCULATION OF LENS POWER

The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon's own experience. The power of the implanted should be determined preoperatively.

### DISCLAIMER OF LIABILITY

The manufacture will not be liable for any injury suffered to patient as a result of:

1. Any implantation method or technique used by a surgeon to implant the lens 2. Any prescription selection and use of the lens for any individual patient or patient's

condition

Adverse reactions and potentially sight threatening complications that may reasonably be regarded as lens related need to be reported to I MEDICAL OPHTHALMIC INTERNATIONAL HEIDELBERG GMBH or Authorized Representative and competent authority of the member state where patient and/or user is located.

### RETURN OF DAMAGED GOODS

Return the lens in its original container to your local distributor with the lot number, style, power, and reason for return.

### PROVISION FOR SSCP

Summary of Safety and Clinical Performance (SSCP) of this device is available on the EUDAMED website https://ec.europa.eu/tools/eudamed
Note: Once the SSCP is reviewed by notified body and uploaded in EUDAMED.

i See instruction for use

Do not resterilise

(2) Do not reuse

A Do not store below 0°C & above 45°C



Do not use if package damaged

Store in dry place



MFG/MD/2020/000163
i-Medical\* Ophthalmic International Heidelberg GmbH Markircher Straße 7 · D-68229 Mannheim · Germany Fax: +49(0)621-484490-20 · www.imedical.de